ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1478

An Orphan Receptor and Osteoarthritis: Mouse Gpr34 Expression in Dorsal Root Ganglia After Partial Meniscectomy

David Thomas1, Terese Geraghty2, Alia Obeidat2, Jun Li2, Rachel Miller2 and Anne-Marie Malfait3, 1University of Minnesota Internal Medicine Residency, St. Paul, MN, 2Rush University Medical Center, Chicago, IL, 3Rush University, Chicago, IL

Meeting: ACR Convergence 2021

Keywords: dorsal root ganglia, macrophages, Mouse Models, Other, Osteoarthritis, pain

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Osteoarthritis & Joint Biology – Basic Science Poster (1468–1479)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Osteoarthritis (OA) is one of the leading causes of musculoskeletal pain and disability. Worldwide, an estimated 303 million patients have clinically diagnosed OA, with over 14 million new cases emerging annually. Yet, management of OA pain remains poor, and often relies on analgesics with limited efficacy. To identify new analgesic targets, we use molecular biology techniques to study the mechanisms underlying OA pain in mouse models. Single cell RNA-sequencing of mouse dorsal root ganglia (DRG) identified novel molecular targets, including several G-protein coupled receptor (GPCR) genes with specific expression patterns in populations of neuronal and non-neuronal DRG cells. In particular, we found that the rhodopsin class GPCR, Gpr34, is specifically expressed by macrophages in the DRG. Given that neuroimmune interactions have been implicated in the development of persistent pain, targets on immune cells infiltrating the DRG may be therapeutically useful. The objective of this study was to investigate expression of Gpr34 by DRG macrophages in experimental OA, induced by partial meniscectomy (PMX). We have previously shown that both male and female mice develop joint damage and signs of pain behavior in this model by 12 weeks post surgery.

Methods: We performed PMX or sham surgery on 10-week-old male and female mice (n=3 per group). Ipsilateral L4 DRG were collected 12 weeks following surgery, fixed in 4% paraformaldehyde, transferred to 30% sucrose solution for cryoprotection and cryo-sectioned onto slides. RNAscope analysis was completed with probes for mouse Gpr34 and Adgre1 per ACD Bio-Techne Multiplex Fluorescent v2 Assay standard protocol. We evaluated macrophage presence in the DRG via immunofluorescence staining for F4/80, a pan-macrophage marker, as previously described. Final images were processed using a Fluoview FV10i confocal microscope, and quantification was completed via ImageJ software. Briefly, in ImageJ, regions of interest (ROIs) were automatically generated from a set intensity threshold and cell size parameters, and the number of positive cells in 30X image area were counted by a blinded observer.

Results: By immunofluorescence, we observed an increase in the total number of F4/80+ cells in DRGs 12 weeks post PMX compared to sham controls, in both male and female mice (n=3) (Figs. 1A+B). In addition, RNAscope in situ hybridization revealed overlap with Gpr34 and Adgre1 (gene name for F4/80) 12 weeks post PMX in male mice, supporting the single cell RNA sequencing data that these cells are indeed macrophages (n=3) (Fig. 1C).

Conclusion: This study suggests that macrophages are increased in the DRGs of both male and female mice after PMX, during a time when the mice have developed both joint damage and persistent pain behaviors. Our lab has previously shown that macrophages numbers also increase in DRGs following destabilization of the medial meniscus (DMM), suggesting that these cells may contribute to the development of persistent pain. Moreover, a novel druggable receptor, Gpr34 is expressed by these macrophages. Future work will examine the contribution of macrophages and Gpr34 to OA pain, and GPR34 and macrophage gene expression in human DRGs.


Disclosures: D. Thomas, Rheumatology Research Foundation, 5; T. Geraghty, NIH NIAMS, 5; A. Obeidat, None; J. Li, None; R. Miller, NIH NIAMS, 5; A. Malfait, Pfizer, 2, Eli Lilly, 2, Ceva, 2, AKP, 2, NIH NIAMS, 5, Galapagos, 5, GlaxoSmithKline, 5.

To cite this abstract in AMA style:

Thomas D, Geraghty T, Obeidat A, Li J, Miller R, Malfait A. An Orphan Receptor and Osteoarthritis: Mouse Gpr34 Expression in Dorsal Root Ganglia After Partial Meniscectomy [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/an-orphan-receptor-and-osteoarthritis-mouse-gpr34-expression-in-dorsal-root-ganglia-after-partial-meniscectomy/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-orphan-receptor-and-osteoarthritis-mouse-gpr34-expression-in-dorsal-root-ganglia-after-partial-meniscectomy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology